MX2020011020A - Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. - Google Patents

Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2.

Info

Publication number
MX2020011020A
MX2020011020A MX2020011020A MX2020011020A MX2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A
Authority
MX
Mexico
Prior art keywords
myosin
isoforms
pharmaceutically effective
effective compounds
compounds inhibiting
Prior art date
Application number
MX2020011020A
Other languages
English (en)
Inventor
Sándor Bátori
András Szabó
József Répási
András Málnási-Csizmadia
Máté Gyimesi
Péter Hári
Suthar Sharad Kumar
Mihály Kovács
Ádám István Horváth
Máté Pénzes
István Lorincz
Zoltán Szonyegi
Zoltán Simon
László Végner
Vajk Horváth
Original Assignee
Printnet Kereskedelmi Es Szolgaltato Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Printnet Kereskedelmi Es Szolgaltato Kft filed Critical Printnet Kereskedelmi Es Szolgaltato Kft
Publication of MX2020011020A publication Critical patent/MX2020011020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) o (II) (ver Fórmulas) sales, solvatos, tautómeros, estereoisómeros farmacéuticamente aceptables de los mismos, incluidos enantiómeros, diastereómeros, mezclas racémicas, mezclas de enantiómeros o combinaciones de los mismos, y usos farmacéuticos de los compuestos.
MX2020011020A 2018-04-18 2019-04-18 Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. MX2020011020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1800129A HU231285B1 (hu) 2018-04-18 2018-04-18 A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
PCT/HU2019/050017 WO2019202346A2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms

Publications (1)

Publication Number Publication Date
MX2020011020A true MX2020011020A (es) 2021-01-08

Family

ID=89992670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011020A MX2020011020A (es) 2018-04-18 2019-04-18 Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2.

Country Status (21)

Country Link
US (2) US11746112B2 (es)
EP (2) EP4276102A3 (es)
JP (1) JP7463344B2 (es)
KR (1) KR20210010465A (es)
CN (2) CN117924285A (es)
AU (1) AU2019256801A1 (es)
BR (1) BR112020021347A2 (es)
CA (1) CA3097479A1 (es)
DK (1) DK3781263T3 (es)
ES (1) ES2963548T3 (es)
FI (1) FI3781263T3 (es)
HU (2) HU231285B1 (es)
IL (1) IL278105B2 (es)
MA (1) MA52298A (es)
MX (1) MX2020011020A (es)
PH (1) PH12020551734A1 (es)
PL (1) PL3781263T3 (es)
PT (1) PT3781263T (es)
SG (1) SG11202010177UA (es)
SI (1) SI3781263T1 (es)
WO (1) WO2019202346A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
US11649234B2 (en) 2018-06-14 2023-05-16 The University Of Florida Research Foundation, Inc. Nonmuscle myosin II inhibitors for substance use relapse

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60420B1 (en) * 1985-06-13 1994-07-13 Schering Corp Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
EP2249837A4 (en) * 2008-01-31 2011-06-15 Univ Monash METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES
WO2010120785A2 (en) 2009-04-13 2010-10-21 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2011137485A1 (en) 2010-05-05 2011-11-10 Sydney Ivf Limited Media and methods for cell culture
EP2492687A1 (en) 2011-02-23 2012-08-29 Institut Gustave Roussy -Igr- MYH10 as a new diagnostic marker of pathologies resulting from RUNX1 inactivation
US9994564B2 (en) * 2011-05-18 2018-06-12 Michael E. DiSanto Myosin II ATPase inhibitor compounds
US9492441B2 (en) 2011-05-18 2016-11-15 Michael E. DiSanto Drug treatment of overactive bladder
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
EP2777703B1 (en) * 2013-03-15 2016-09-14 Lonza Cologne GmbH Compositions and methods for enhancing the therapeutic potential of stem cells
US20170029886A1 (en) * 2014-02-18 2017-02-02 Etablissement Francais Du Sang High-resolution hla typing
EP3277799B1 (en) 2015-04-03 2020-09-23 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2016180918A1 (en) 2015-05-12 2016-11-17 Platod Combination of pharmacological and microfluidic features for improved platelets production
EP3529249A1 (en) * 2016-01-29 2019-08-28 Paris Sciences et Lettres - Quartier Latin Water-soluble myosin 2 inhibitors for the treatment of neurological, neuropathic or psychiatric diseases
JP2021514010A (ja) 2018-02-20 2021-06-03 エッジワイズ セラピューティクス， インコーポレイテッド 運動障害を処置するための方法および組成物
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
US11649234B2 (en) 2018-06-14 2023-05-16 The University Of Florida Research Foundation, Inc. Nonmuscle myosin II inhibitors for substance use relapse
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf

Also Published As

Publication number Publication date
CN117924285A (zh) 2024-04-26
PT3781263T (pt) 2023-10-13
HUE063424T2 (hu) 2024-01-28
PL3781263T3 (pl) 2024-01-22
BR112020021347A2 (pt) 2021-01-19
WO2019202346A2 (en) 2019-10-24
EP3781263A2 (en) 2021-02-24
US20230339959A1 (en) 2023-10-26
DK3781263T3 (da) 2023-10-02
WO2019202346A3 (en) 2019-12-19
PH12020551734A1 (en) 2021-06-07
CN112334191A (zh) 2021-02-05
SI3781263T1 (sl) 2024-01-31
HUP1800129A1 (hu) 2019-10-28
SG11202010177UA (en) 2020-11-27
IL278105A (es) 2020-12-31
JP2021522322A (ja) 2021-08-30
IL278105B1 (en) 2024-01-01
EP4276102A2 (en) 2023-11-15
FI3781263T3 (fi) 2023-09-15
AU2019256801A1 (en) 2020-12-17
US20210087201A1 (en) 2021-03-25
CA3097479A1 (en) 2019-10-24
KR20210010465A (ko) 2021-01-27
MA52298A (fr) 2021-02-24
US11845758B2 (en) 2023-12-19
HU231285B1 (hu) 2022-08-28
JP7463344B2 (ja) 2024-04-08
ES2963548T3 (es) 2024-03-27
EP4276102A3 (en) 2023-12-06
US11746112B2 (en) 2023-09-05
EP3781263B1 (en) 2023-07-12
IL278105B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
PH12016501440A1 (en) Novel heterocyclic compounds
MX2020000261A (es) Nuevos compuestos.
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2019005306A (es) Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2019005234A (es) Amidas y aminas de azol como inhibidores de integrina alfa v.
MX2019005233A (es) Pirrolamidas como inhibidores de la integrina alfa v.
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12020551734A1 (en) Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
MX2022000939A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos.
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
EA202090653A1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение